Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

Table 1 Patient demographics

Patient number	Age(years)	Sex	HLA- type	Previous treatments	Tumor burden (cm)	AJCC stage	Metastatic sites
1	60	F	A2	IL2/INF, brain surgery	3.9	M1c	LN, brain^a
2	47	M	A2/A3	IL2/IFN, DC-vac, abdominal surgery	22.8	M1c	LN, intestines
3	62	M	A3/A11	IL2/IFN, DC-vac	15.5	M1c	SC, lung, stomach, gall bladder
6	36	M	A2	IL2/IFN	8.6	M1c	LN, liver, bone
7	61	M	A2/A24	IL2/INF, CD137, DC-vac, brain surgery	19.8	M1c	LN, lung, bone, brain^a
11	41	M	A1/A3	IL2/INF, Ipilimumab, DC-vac	3.5	M1a	LN, SC

PS: performance status, AJCC: American Joint Committee on Cancer, M:male, F:female, IL2/INF:Interleukin-2/Interferon-α (according to the treatment regimen described by Keilholz et al. ref. 20), DC-vac: dendritic cell vaccine (experimental treatment), CD137:CD137 antibody (experimental treatment), LN: lymphnode metastasis, SC: subcutaneuous metastasis. Tumor burden was defined as the sum of all measurable lesions (>1 cm in longest diameter) up to a maximum of 10 lesions (according to RECIST 1.0). ^aBrain metastases were surgically removed before inclusion in the protocol.

ISSN: 1479-5876